• In its recent third-quarter fiscal 2026 update, Amcor reported adjusted earnings in line with expectations, higher net sales supported by the Berry acquisition, improved margins, and a reduced full-year outlook tied to inventory and supply issues linked to Middle East conflict.
• At the same time, Amcor has been expanding its healthcare packaging footprint with new cleanroom certification in Puerto Rico and a manufacturing expansion in India, underscoring a growing emphasis on higher-value medical and pharmaceutical packaging.
• We’ll now examine how Amcor’s lower full-year guidance and healthcare-focused capacity expansions affect its existing investment narrative and assumptions.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Amcor Investment Narrative Recap

To own Amcor, you need to believe the Berry integration and portfolio reshaping can offset soft volumes, high leverage, and a still‑underperforming North American beverage arm. The latest quarter delivered in‑line earnings and better margins, but the lower full‑year guidance tied to Middle East supply disruption keeps execution risk front and center, especially around cash generation and the timing of any portfolio actions. For now, this news reframes near‑term expectations rather than overturning the core thesis.

Among recent announcements, the cleanroom certification in Puerto Rico and the capacity expansion in India speak directly to one of Amcor’s key catalysts: shifting more of the business toward higher value healthcare packaging. These moves sit alongside the Berry integration and Asia‑Pacific buildout, potentially helping counterbalance weaker end markets elsewhere. How far that healthcare tilt can blunt risks around leverage, restructuring, and divestitures will depend on how quickly these new facilities ramp and contribute.

Yet, despite these positives, the combination of softer guidance, high leverage and a large portfolio under review is something investors should be very aware of...

Amcor's narrative projects $23.9 billion revenue and $1.6 billion earnings by 2029. This requires 2.6% yearly revenue growth and about a $0.9 billion earnings increase from $678.0 million today.

Uncover how Amcor's forecasts yield a $48.21 fair value, a 26% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were once assuming Amcor could reach about US$25.8 billion in revenue and US$2.3 billion in earnings by 2028, so if you lean toward that view you are embracing a far rosier outcome than consensus and the recent guidance reset suggest, highlighting just how far opinions differ and why it is worth weighing several competing scenarios before deciding what you believe.

Explore 6 other fair value estimates on Amcor - why the stock might be worth as much as 94% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Amcor research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Amcor research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amcor's overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Find 49 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.